A preliminary study of recombinant human interleukin 2 therapy was made in 8 patients with chronic hepatitis B. They received 250 to 1, 000 units per day of interleukin 2 for 28 consecutive days. Fever, fatigue, and anorexia were the major side effects, although all of them were resolved after interleukin 2 administration was discontinued. Serum deoxyribonucleic acid (DNA) polymerase activity decreased in all patients during the administration of interleukin 2. There was an abrupt rise in serum alanine aminotransferase level associated with a fall in serum DNA polymerase level in 5 of the patients. One patient had sustained losses of hepatitis B e antigen and DNA polymerase. Recombinant interleukin 2 therapy may be of benefit in some hepatitis B virus carriers, although further development of this approach and additional patient follow-ups are required.
I. Introduction
Accumulating evidence has suggested that cellular immunity may play an essential role in the pathogenesis of viral hepatitis B as well as in virus elimination1"2). The immunity against the latter is thought to be reduced or deficient in chronic carriers of hepatitis B virus antigens').
Since these carriers often develop severe liver diseases including hepatocellular carcinoma4>, many attempts have been made to potentiate specific immunity against virus antigens with immunostimulantss"3). However, no promising results have so far been obtained. Interleukin 2, originally called the T cell growth factor, is a lymphokine produced by T cells when they are activated with lectins or alloantigens9). It has been demonstrated to be a critical factor for the growth of T cells, and it is able to augment various T cell functions"") as well as natural killer (NK) cell activity14). Moreover, the recent availability of purified recombinant interleukin 2 from Escherichia coli expressing the gene for human interleukin 2 has allowed its evaluation as a therapeutic reagent in patients [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . In the present study, we examined the efficacy and toxicity of recombinant interleukin 2 in a pilot study of interleukin 2 therapy in patients with chronic hepatitis B. They received 250 to 1,000 units per day of interleukin 2 for 28 consecutive days ( Fig. 1 ). Recombinant interleukin 2 was diluted in 250 ml of normal saline, and this was infused intravenously over a 30 minute period every day at 1 : 00 p.m. The patients were discharged from the hospital 4 weeks after treatment and were seen in the outpatient clinic every one to 2 weeks. Pretreatment liver biopsy was performed in all patients, and in 5 patients, it was also performed after treatment.
Methods
For safety, blood samples were obtained weekly during therapy and every 2 to 4 weeks thereafter. were obtained before and within 2 weeks after treatment. The two biopsy specimens were compared, and the degree of hepatitis and the presence or absence of cirrhosis were determined.
III. Results

Antiviral activity
To assess the interleukin 2-induced response of DNA polymerase activity, percent reduction of DNA polymerase during treatment was calculated (Fig. 2) . Serum DNA polymerase activity decreased in all the patients during interleukin 2 administration. In one patient (Patient No. 7), HBe Ag became negative 2 weeks after treatment, but he did not develop HBe Ab after therapy (Fig. 3) . In 2 cases, serum DNA polymerase activity returned to pretreatment level within 2 weeks after treatment. Thus, interleukin 2 led to a temporary inhibition of serum DNA polymerase activity in most patients, and the enzyme level increased once therapy was stopped in some cases.
Liver function test
An elevation in serum ALT level was observed during treatment in 5 cases. The peak of this enzyme was noted in the second or third week (Fig.   4 ). The typical ALT peak does not appear to be due to dose-related interleukin 2 hepatotoxicity. In patient No. 3, 4, and 7, serum ALT level markedly increased during treatment, which occurred simultaneously with or just before the decrease in serum DNA polymerase activity ( Fig. 2 and 4 ). As shown in Fig. 3 , a slight increase in serum bilirubin level was observed during treatment in only one case (Patient No. 7). The elevated level of serum ALT returned to pretreatment level within 2 weeks after treatment.
Side effects
Fever, chilliness, " influenza-like " symptoms, myalgia, headache, and fatigue occurred during treatment, irrespective of the dose given (Table 2) .
Pulmonary, hematologic, and renal toxicity and 
Liver biopsies
Post-treatment biopsy specimens were obtained from 5 of the patients within 2 weeks after the end of treatment (Table 1) single cell necrosis were more prominent after interleukin 2 therapy.
IV. Discussion
Interleukin 2 is a lymphokine that plays an important role in a variety of immune reactions. This lymphokine is produced by T cells stimulated with mitogens or antigens, and modulates the proliferation and / or differentiation of T, B, and NK cells through interaction with highly specific receptors on their cell surfaces9"19). On the basis of these facts, it has been presumed that interleukin 2 might be therapeutically useful to augment immune responses in vivo22). Recently, the production of human interleukin 2 from Escherichia coli by recombinant DNA technology has increased the supply and purity of this lymphokinel5"20>, and it is being used for the treatment of cancer21) and acquired immunodeficiency syndrome (AIDS)21). However, the efficacy and toxicity of purified recombinant interleukin 2 in chronic hepatitis B are unknown.
In this study, we investigated the clinical and adverse effects and the antiviral activity of such a preparation in a pilot study of interleukin 2 therapy in patients with chronic hepatitis B.
DNA polymerase activity decreased soon after the start of interleukin 2 treatment in all patients, but viral replication returned to pretreatment level by the end of treatment in 2 patients. 
